Key Takeaways
- A 20-year study monitoring nearly 2800 women suggests starting HRT during perimenopause or early menopause may reduce the risk of heart attacks and stroke.
- HRT, available in tablet form, may offer systemic advantages beyond easing standard menopause symptoms.
- Lead researcher Samar El Khoudary stressed, “I want to emphasise: our study does not support using menopausal [hormonal] therapy to prevent cardiovascular disease,” noting that more research is needed to establish optimal timing and mechanisms.
Long-term tracking reveals potential cardiovascular protection
Hormone replacement therapy administered during perimenopause or early menopause may offer benefits that extend beyond the relief of typical menopausal symptoms. A comprehensive investigation following nearly 2800 women over a 20-year span indicates that starting the treatment around this transitional timeframe is associated with a reduced risk of experiencing serious cardiovascular events, including heart attacks and strokes.
Hormone replacement therapy, which is available in tablet form, has long been utilized to ease discomfort associated with menopause. The long-term tracking of participants suggests an intriguing link between early intervention and cardiovascular health, opening new questions about how hormone treatments interact with the body’s vascular system.
Researchers emphasize need for further investigation
Despite the encouraging correlation, scientists urge caution and stress that the findings should not be interpreted as a directive for preventative medicine. Substantial additional research is needed to determine the exact mechanisms driving these effects and to identify the optimal timing for taking the therapy.
“I want to emphasise: our study does not support using menopausal [hormonal] therapy to prevent cardiovascular disease,” explains Samar El Khoudary of Virginia Commonwealth University, highlighting the importance of understanding the therapy’s biological pathways before drawing clinical recommendations.
